Inhibrx Biosciences, Inc. (INBX:NASDAQ) closed at $95.66 on October 27, 2026, up 7.96% on the day. The stock trades 38.4% below its 52-week high of $155.29 and 66.9% above its 52-week low of $57.30. Over the past year, it gained 50.6%. Inhibrx Biosciences, Inc. is part of the Health Care sector.
In 252 trading sessions since October 27, 2025, INBX closed higher on 125 days (50%). Its best day was April 22, 2026 (+36.88%) and its worst was May 12, 2026 (-14.84%). The stock moved 10% or more in a single session 12 times. It opened at least 5% above the previous day's high 3 times.
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Find more stocks like INBX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.